| Literature DB >> 29340818 |
Mateusz Wierdak1, Magdalena Pisarska1,2, Beata Kuśnierz-Cabala3, Jan Witowski1,2, Jadwiga Dworak1, Piotr Major1,2, Piotr Małczak1,2, Piotr Ceranowicz4, Andrzej Budzyński1,2, Michał Pędziwiatr5,6.
Abstract
BACKGROUND: Combination of laparoscopic approach with ERAS protocol in colorectal surgery allows for an early discharge. However there is a risk that some of the discharged patients are developing, asymptomatic at the time, infectious complications. This may lead to a delay in diagnostics and proper treatment introduction. We aimed to assess the usefulness of preoperative plasma albumin concentration and their changes as indicators of infectious complications in patients undergoing colorectal cancer surgery.Entities:
Keywords: Albumins; Colorectal cancer; Infectious complications; Laparoscopy; Markers
Mesh:
Substances:
Year: 2018 PMID: 29340818 PMCID: PMC5988762 DOI: 10.1007/s00464-018-6040-4
Source DB: PubMed Journal: Surg Endosc ISSN: 0930-2794 Impact factor: 4.584
ERAS protocol used in our unit
| 1 Preoperative counselling and patient’s education |
| 2 No bowel preparation (oral lavage in the case of low rectal resection with TME and defunctioning loop ileostomy) |
| 3 Preoperative carbohydrate loading (400 ml of Nutricia preOp® 2 h prior surgery) |
| 4 Antithrombotic prophylaxis (Clexane® 40 mg sc. starting in the evening prior surgery) |
| 5 Antibiotic prophylaxis (preoperative cefuroxime 1.5 g + metronidazole 0.5 g iv. 30–60 min prior surgery) |
| 6 Laparoscopic surgery |
| 7 Balanced intravenous fluid therapy (< 2500 ml intravenous fluids during the day of surgery, less than 150 mmol sodium) |
| 8 No nasogastric tubes postoperatively |
| 9 No drains left routinely for colonic resections, one drain placed for < 24 h in case of TME |
| 10 Transversus abdominis plane (TAP) block, epidural anaesthesia in cases with high risk of conversion |
| 11 Avoiding opioids, multimodal analgesia (oral when possible—paracetamol 4 × 1 g, ibuprofen 2 × 200 mg, metamizole 2 × 2.5 g, or ketoprofen 2 × 100 mg) |
| 12 Prevention of postoperative nausea and vomiting (PONV) (dexamethasone 8 mg iv., ondansetron 8 mg iv., metoclopramide 10 mg iv.) |
| 13 Postoperative oxygenation therapy (4–6 l/min) |
| 14 Early oral feeding (oral nutritional supplement 4 h postoperatively, light hospital diet and oral nutritional supplements on the first postoperative day, full hospital diet on the second postoperative day) |
| 15 Urinary catheter removal on the first postoperative day |
| 16 Full mobilisation on the first postoperative day (getting out of bed, going to toilet, walking along the corridor, at least 4 h out of bed) |
Fig. 1Patients flow through the study
Demographic analysis of patient groups
| Parameter | Group 1 | Group 2 | |
|---|---|---|---|
| Number of patients [n (%)] | 82 (78.1%) | 23 (21.9%) | – |
| Females [n (%)] | 39 (47.6%) | 12 (52.2%) | 0.69572 |
| Males [n (%)] | 43 (52.4%) | 11 (47.8%) | |
| Mean age (years ± SD) | 63.2 ± 13.4 | 65.3 ± 13.5 | 0.62947 |
| BMI (kg/m2 ± SD) | 26.7 ± 5.0 | 26.8 ± 5.0 | 0.75312 |
| ASA 1 [n (%)] | 1 (1.2%) | 1 (4.3%) | 0.6609 |
| ASA 2 [n (%)] | 53 (64.6%) | 14 (60.9%) | |
| ASA 3 [n (%)] | 27 (33%) | 7 (30.4%) | |
| ASA 4 [n (%)] | 1 (1.2%) | 1 (4.3%) | |
| Any comorbidity [n (%)] | 64 (78%) | 17 (73.9%) | 0.67663 |
| Cardiovascular [n (%)] | 30 (36.6%) | 8 (34.8%) | 0.87442 |
| Hypertension [n (%)] | 42 (51.2%) | 12 (52.2%) | 0.93331 |
| Diabetes [n (%)] | 15 (18.3%) | 5 (21.7%) | 0.71028 |
| Pulmonary disease [n (%)] | 6 (7.3%) | 3 (13%) | 0.38584 |
| Renal disease [n (%)] | 6 (7.3%) | 2 (8.7%) | 0.82658 |
| Liver disease [n (%)] | 4 (4.9%) | 1 (4.3%) | 0.91647 |
| AJCC Stage I [n (%)] | 37 (45.1%) | 10 (43.5%) | 0.63179 |
| AJCC Stage II [n (%)] | 24 (29.3%) | 5 (21.7%) | |
| AJCC Stage III [n (%)] | 21 (25.6%) | 8 (34.8%) | |
| Colonic resection [n (%)] | 53 (64.6%) | 16 (69.6%) | 0.65748 |
| Rectal resection [n (%)] | 29 (35.4%) | 7 (30.4%) | |
| Mean operative time (min ± SD) | 194.4 ± 56.7 | 215.3 ± 73.3 | 0.44429 |
| Median operative time [min (IQR)] | 190 (160–230) | 180 (170–275) | |
| Mean intraoperative blood loss (ml ± SD) | 113.0 ± 118.4 | 128.4 ± 107.6 | 0.55006 |
| Median intraoperative blood loss [ml (IQR)] | 100 (50–150) | 100 (50–200) | |
| Mean length of hospital stay (days, range) | 4.8 ± 4.0 | 10.8 ± 6.7 | 0.00003 |
| Median length of hospital stay (days, IQR) | 4 (3–6) | 9 (6–18) | |
| Readmission [n (%)] | 4 (4.9%) | 4 (17.4%) | 0.04561 |
Types of complications
| Anastomotic leakage | 9 (8.6%) |
| Surgical site infection—deep or superficial | 6 (5.7%) |
| Intraperitoneal abscess | 2 (1.9%) |
| Urinary tract infection | 3 (2.8%) |
| Pneumonia | 2 (1.9%) |
| Infectious diarrhoea (C. difficile) | 1 (1.0%) |
Analysis of biochemical parameters
| Parameter | Group 1 | Group 2 | ||
|---|---|---|---|---|
| Mean albumin ± SD (median, IQR) (g/l) | POD 0 | 38.7 ± 4.9 (39, 36–42) | 37.7 ± 5.0 (40, 35–41) | 0.58702 |
| POD 1 | 36.5 ± 4.2 (37, 34–39) | 34.7 ± 4.2 (35, 30–37) | 0.07131 | |
| POD 2 | 36.2 ± 4.1 (37, 34–39) | 32.6 ± 5.6 (33, 30–36) | 0.00996 | |
| POD 3 | 36.0 ± 4.4 (36, 34–39) | 30.9 ± 3.5 (31, 28–32) | 0.00004 | |
| Δ-albumin ± SD (median) (g/l) | POD 1 | − 2.6 ± 4.1 (− 2, − 5 to 1) | − 3.0 ± 4.6 (− 4, − 6 to 0) | 0.68309 |
| POD 2 | − 2.9 ± 4.5 (− 3, − 6 to 0) | − 5.2 ± 5.3 (− 6, − 8 to − 1) | 0.04953 | |
| POD 3 | − 3.2 ± 4.4 (− 3, − 6 to 0) | − 7.2 ± 4.7 (− 7, − 10 to − 5) | 0.00306 | |
| Albumin POD 1/POD 0, mean ± SD (median, IQR) | 0.94 ± 0.09 (0.94, 0.88–1.02) | 0.93 ± 0.13 (0.9, 0.85–1) | 0.27379 | |
| Albumin POD 2/POD 0, mean ± SD (median, IQR) | 0.93 ± 0.11 (0.93, 0.84–1.0) | 0.83 ± 0.24 (0.86, 0.79–0.94) | 0.02905 | |
| Albumin POD 3/POD 0, mean ± SD (median, IQR) | 0.92 ± 0.11 (0.91, 0.83–1.0) | 0.82 ± 0.11 (0.82, 0.76–0.89) | 0.00481 | |
| Albumin POD 2/POD 1, mean ± SD (median, IQR) | 0.99 ± 0.1 (1, 0.94–1.05) | 0.92 ± 0.1 (0.9, 0.86–1.03) | 0.01294 | |
| Albumin POD 3/POD 1, mean ± SD (median, IQR) | 1.0 ± 0.12 (0.97, 0.86–1.03) | 0.87 ± 0.08 (0.86, 0.83–0.91) | 0.00002 | |
Fig. 2Mean albumin levels in Group 1 and Group 2 in consecutive days
Fig. 3Mean Δ-albumin increments in Group 1 and Group 2 in consecutive days
Fig. 4Albumin ratios in Group 1 and Group 2 in consecutive days
Fig. 5Receiver operating characteristic (ROC) curve to determine the optimal cut-off of albumin measurements
Fig. 6Receiver operating characteristic (ROC) curve to determine the optimal cut-off of Δ-albumin measurements
Fig. 7Receiver operating characteristic (ROC) curve to determine the optimal cut-off of albumin ratio measurements (POD0)
Fig. 8Receiver operating characteristic (ROC) curve to determine the optimal cut-off of albumin ratio measurements (POD1)